Cardiovascular

ADEMPAS® (riociguat) is licensed as monotherapy or in combination with endothelin receptor antagonists (ERA’s), for the treatment of adult patients with PAH with WHO Functional Class (FC) II to III to improve exercise capacity.¹

ADEMPAS (riociguat) is also licensed for the treatment of adult patients with WHO functional class II to III with:

inoperable CTEPH
persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity.

More information about ADEMPAS (riociguat):

Visit product page

Congress learnings

General ItemothercvCongress01250tcm:4244-1129910ERS Congress: Dr Jim Lordan and Wendy Gin-Sing/static/mciuk/images/ig0746_cv_resource_ers-2019_thumb@2x.png/therapy-areas/Cardiovascular/drlordan-gin-sing.xhtml <a href="http://www.msdproduct.co.uk/api/adempas.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>cvCongress/static/mciuk/images/ig0746_cv_resource_ers-2019_thumb@2x.pngassetIdtcm:4244-1129910pathologiesCardiovascularlocalproductnameEzetrolglobalproductnameEzetrolkeywordsIMPROVE-IT,ezetimibe,ezetrolspecialityexpirationdatepublicationdatecodextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupassettypeDocumentassetfranchiseDiabetes & Cardiovascularasset_descriptionThis page contains video information about Ezetrol (ezetimibe) indication and IMPROVE-IT trial and is intended only for UK Healthcare Professionals.asset_purposeClinical informationasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagstcm:4244-1129913PVRI Congress: Day 1/static/mciuk/images/ig0746_cv_resource_pvri-2019_thumb@2x.png/therapy-areas/Cardiovascular/day-1.xhtml <a href="http://www.msdproduct.co.uk/api/adempas.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>cvCongress/static/mciuk/images/ig0746_cv_resource_pvri-2019_thumb@2x.pngassetIdtcm:4244-1129913pathologiesCardiovascularlocalproductnameEzetrolglobalproductnameEzetrolkeywordsIMPROVE-IT,ezetimibe,ezetrolspecialityexpirationdatepublicationdatecodextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupassettypeDocumentassetfranchiseDiabetes & Cardiovascularasset_descriptionThis page contains video information about Ezetrol (ezetimibe) indication and IMPROVE-IT trial and is intended only for UK Healthcare Professionals.asset_purposeClinical informationasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtags

Rating

ERS Congress: Dr Jim Lordan and Wendy Gin-Sing

Prescribing Information

Rating

PVRI Congress: Day 1

Prescribing Information

< Previous 1 Next >

General ItemothercvCongress01250tcm:4244-1129910ERS Congress: Dr Jim Lordan and Wendy Gin-Sing/static/mciuk/images/ig0746_cv_resource_ers-2019_thumb@2x.png/therapy-areas/Cardiovascular/drlordan-gin-sing.xhtml <a href="http://www.msdproduct.co.uk/api/adempas.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>cvCongress/static/mciuk/images/ig0746_cv_resource_ers-2019_thumb@2x.pngassetIdtcm:4244-1129910pathologiesCardiovascularlocalproductnameEzetrolglobalproductnameEzetrolkeywordsIMPROVE-IT,ezetimibe,ezetrolspecialityexpirationdatepublicationdatecodextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupassettypeDocumentassetfranchiseDiabetes & Cardiovascularasset_descriptionThis page contains video information about Ezetrol (ezetimibe) indication and IMPROVE-IT trial and is intended only for UK Healthcare Professionals.asset_purposeClinical informationasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagstcm:4244-1129913PVRI Congress: Day 1/static/mciuk/images/ig0746_cv_resource_pvri-2019_thumb@2x.png/therapy-areas/Cardiovascular/day-1.xhtml <a href="http://www.msdproduct.co.uk/api/adempas.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>cvCongress/static/mciuk/images/ig0746_cv_resource_pvri-2019_thumb@2x.pngassetIdtcm:4244-1129913pathologiesCardiovascularlocalproductnameEzetrolglobalproductnameEzetrolkeywordsIMPROVE-IT,ezetimibe,ezetrolspecialityexpirationdatepublicationdatecodextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupassettypeDocumentassetfranchiseDiabetes & Cardiovascularasset_descriptionThis page contains video information about Ezetrol (ezetimibe) indication and IMPROVE-IT trial and is intended only for UK Healthcare Professionals.asset_purposeClinical informationasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtags

Reference

ADEMPAS Summary of Product Characteristics.

Supporting documentation

ADEMPAS^® (riociguat)
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-ADE-00274 | Date of Preparation: March 2020

Welcome to MSD Connect

Thank you